Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population

Simple item page
dc.contributor.authorFernandez-Mateos, J.
dc.contributor.authorSeijas-Tamayo, R.
dc.contributor.authorMesia, R.
dc.contributor.authorTaberna, M.
dc.contributor.authorPastor Borgonon, M.
dc.contributor.authorPerez-Ruiz, E.
dc.contributor.authorKlain, J. C. Adansa
dc.contributor.authorVazquez Fernandez, S.
dc.contributor.authordel Barco Morillo, E.
dc.contributor.authorLozano, A.
dc.contributor.authorGonzalez Sarmiento, R.
dc.contributor.authorCruz-Hernandez, J. J.
dc.contributor.authorSpanish Head Neck Canc Cooperative
dc.contributor.authoraffiliation[Fernandez-Mateos, J.] Univ Hosp Salamanca, Med Oncol Serv, IBSAL, Paseo San Vicente 5-182, Salamanca 37007, Spain
dc.contributor.authoraffiliation[Seijas-Tamayo, R.] Univ Hosp Salamanca, Med Oncol Serv, IBSAL, Paseo San Vicente 5-182, Salamanca 37007, Spain
dc.contributor.authoraffiliation[Klain, J. C. Adansa] Univ Hosp Salamanca, Med Oncol Serv, IBSAL, Paseo San Vicente 5-182, Salamanca 37007, Spain
dc.contributor.authoraffiliation[del Barco Morillo, E.] Univ Hosp Salamanca, Med Oncol Serv, IBSAL, Paseo San Vicente 5-182, Salamanca 37007, Spain
dc.contributor.authoraffiliation[Cruz-Hernandez, J. J.] Univ Hosp Salamanca, Med Oncol Serv, IBSAL, Paseo San Vicente 5-182, Salamanca 37007, Spain
dc.contributor.authoraffiliation[Fernandez-Mateos, J.] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, SACYL, CSIC, Salamanca, Spain
dc.contributor.authoraffiliation[Seijas-Tamayo, R.] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, SACYL, CSIC, Salamanca, Spain
dc.contributor.authoraffiliation[Klain, J. C. Adansa] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, SACYL, CSIC, Salamanca, Spain
dc.contributor.authoraffiliation[del Barco Morillo, E.] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, SACYL, CSIC, Salamanca, Spain
dc.contributor.authoraffiliation[Gonzalez Sarmiento, R.] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, SACYL, CSIC, Salamanca, Spain
dc.contributor.authoraffiliation[Cruz-Hernandez, J. J.] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, SACYL, CSIC, Salamanca, Spain
dc.contributor.authoraffiliation[Fernandez-Mateos, J.] Univ Salamanca, Dept Med, Mol Med Unit, IBSAL, Campus Miguel Unamuno, Salamanca 37007, Spain
dc.contributor.authoraffiliation[Gonzalez Sarmiento, R.] Univ Salamanca, Dept Med, Mol Med Unit, IBSAL, Campus Miguel Unamuno, Salamanca 37007, Spain
dc.contributor.authoraffiliation[Cruz-Hernandez, J. J.] Univ Salamanca, Dept Med, Mol Med Unit, IBSAL, Campus Miguel Unamuno, Salamanca 37007, Spain
dc.contributor.authoraffiliation[Fernandez-Mateos, J.] Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc IBMCC, Salamanca, Spain
dc.contributor.authoraffiliation[Gonzalez Sarmiento, R.] Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc IBMCC, Salamanca, Spain
dc.contributor.authoraffiliation[Mesia, R.] Inst Catala Oncol LHospitalet de Llobregat, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Taberna, M.] Inst Catala Oncol LHospitalet de Llobregat, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Vazquez Fernandez, S.] Inst Catala Oncol LHospitalet de Llobregat, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Pastor Borgonon, M.] Hosp Univ Politecn La Fe, Med Oncol Serv, Valencia, Spain
dc.contributor.authoraffiliation[Perez-Ruiz, E.] Hosp Costa del Sol, Div Med Oncol, Dept Oncol, Marbella, Spain
dc.contributor.authoraffiliation[Lozano, A.] Inst Catala Oncol LHospitalet, Dept Radiat Oncol, Barcelona, Spain
dc.contributor.funderI+D+i of Junta de Castilla y Leon
dc.contributor.funder"Fondo FIS" of ISCIIII
dc.date.accessioned2025-01-07T14:46:28Z
dc.date.available2025-01-07T14:46:28Z
dc.date.issued2016-12-01
dc.description.abstractObjectives: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab.Material and methods: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase chain reaction-restriction fragment length polymorphism methods.Results: Acneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p
dc.identifier.doi10.1016/j.oraloncology.2016.10.006
dc.identifier.essn1879-0593
dc.identifier.issn1368-8375
dc.identifier.pmid27938998
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.oraloncology.2016.10.006
dc.identifier.urihttps://hdl.handle.net/10668/26658
dc.identifier.wosID392637300011
dc.journal.titleOral oncology
dc.journal.titleabbreviationOral oncol.
dc.language.isoen
dc.organizationSAS - Hospital Costa del Sol
dc.page.number38-43
dc.publisherElsevier science bv
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHead and neck squamous cell carcinoma (HNSCC)
dc.subjectEpidermal growth factor receptor (EGFR)
dc.subjectPolymorphism
dc.subjectSNP
dc.subjectEGFR
dc.subjectCCDN1
dc.subjectFCGR2A
dc.subjectFCGR3A
dc.subjectKRAS-LCS6
dc.subjectCetuximab
dc.subjectToxicity
dc.subjectPlatinum-based chemotherapy
dc.subjectPhase-ii
dc.subjectPlus cetuximab
dc.subjectSkin toxicity
dc.subjectSingle-agent
dc.subjectLung-cancer
dc.subjectOpen-label
dc.subjectRisk
dc.subjectEpidemiology
dc.subjectCombination
dc.titleEpidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number63
dc.wostypeArticle

Files

Collections

SAS - Hospital Costa del Sol

Ā© 2023 ā€“ Repositorio Institucional de Salud de AndalucĆ­a - FundaciĆ³n PĆŗblica Andaluza Progreso y Salud - ConsejerĆ­a de Salud y Consumo de la Junta de AndalucĆ­a